Pharmafile Logo

OTC Awards

- PMLiVE

Amgen announces plans to acquire Horizon for $27.8bn in biggest pharma deal for 2022

The acquisition will see Amgen pay $116.50 for each Horizon share in cash

- PMLiVE

AbbVie receives extended SMC recommendation for Rinvoq in rheumatoid arthritis patients

In Scotland, there are around 44,000 people living with the progressive autoimmune disease

- PMLiVE

Janssen’s Imbruvica shows promise in chronic lymphocytic leukaemia study

The data was shared during the 2022 American Society of Hematology Annual Meeting

- PMLiVE

Roche shares phase 3 Polivy data for previously untreated diffuse large B-cell lymphoma

Results continue to show significant reduction in risk of death for DLBCL patients

- PMLiVE

WHO member states commit to producing a pandemic accord in 2023

The ‘zero draft’ will be a legally binding agreement, part of the WHO Constitution

- PMLiVE

New UK study finds most MS patients not offered fatigue treatments

Of 4,367 patients surveyed, 30.8% reported having been offered at least one treatment for fatigue

- PMLiVE

Pfizer shares updated pivotal phase 2 elranatamab data for multiple myeloma

There are 176,000 new cases of the disease worldwide for which there is currently no cure

- PMLiVE

UK Government launches new taskforce to help NHS tackle COVID-19 backlogs

Experts will focus on how the NHS can utilise existing capacity in the independent sector

- PMLiVE

Kite and Arcellx partner to develop and commercialise multiple myeloma candidate

Arcellx is set to receive an upfront cash payment of $225m and $100m equity investment

- PMLiVE

WHO report provides data for high levels of antimicrobial resistance in bacteria

GLASS involved 72% of the world’s population, achieving participation from 127 countries

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links